Poliadenopatías mediastinales y diagnósticos diferenciales en lupus eritematoso sistémico. Reporte de un caso y revisión de la literatura

Rosana Quintana; M. Emilia Sattler; Marisol Ferrer

doi:10.47196/rar.v30i3.444

Rosana Quintana Centro Regional en Enfermedades Autoinmunes y Reumáticas del Grupo Oroño (GO-CREAR), Rosario, Argentina
M. Emilia Sattler Hospital Escuela Eva Perón, Granadero Baigorria, Rosario, Argentina
Marisol Ferrer Sanatorio Parque, Rosario, Argentina

DOI: https://doi.org/10.47196/rar.v30i3.444

Palabras clave: Poliadenopatías, mediastino, Lupus eritematoso sistémico

Resumen

Paciente varón de 59 años de edad con diagnóstico de lupus eritematoso sistémico y cuadro de consolidación pulmonar asociada a poliadenopatías mediastinales y derrame pleural, con evolución crónica y tórpida. Se discuten diagnósticos diferenciales e implicancia clínica.

Biografía del autor/a

M. Emilia Sattler, Hospital Escuela Eva Perón, Granadero Baigorria, Rosario, Argentina

Servicio de Reumatología

Marisol Ferrer, Sanatorio Parque, Rosario, Argentina

Servicio de Anatomía Patológica

Citas

I. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.

II. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31(3):479-88.

III. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.

IV. Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585-96.

V. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-6.

VI. Manual SER de diagnóstico y tratamiento de las enfermedades reumáticas autoinmunes sistémicas. Elsevier. 2014.

VII. Battagliotti C. et al. Vasculitis. Toma de desiciones. Buenos Aires, 2012.

VIII. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286-94.

IX. Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, et al. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol. 2013;5(7):387-92.

X. Guías de hepatitis virales. Ministerio de Salud de la Nación. 2016.

XI. Salman-Monte TC, Lisbona MP, Garcia-Retortillo M, Maymo J. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin. 2014;10(3):196-7.

XII. T LS. Conexión entre inmunodeficiencia y autoinmunidad. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2010;26(1):198-205.

XIII. D FR. Inmunodeficiencia común variable. Epidemiología y manifestaciones clínicas en 69 pacientes. MEDICINA (Buenos Aires) 2013;73:315-323.

XIV. Adeleye A, Kelly M, Wright NA, Yu W, Anselmo MA. Granulomatous lymphocytic interstitial lung disease in infancy. Can Respir J. 2014;21(1):20-2.

XV. Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.

XVI. Knight JS, Blayney DW, Somers EC. Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. Lupus Sci Med. 2014;1(1):e000051.

XVII. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus. 2009;18(6):479-85.

XVIII. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, et al. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(10):1507-9.

XIX. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60.

XX. Chen Y, Ding C, Lin Q, Yang K, Li Y, Chen S. Primary intravascular large B-cell lymphoma of the lung: a review and case report. J Thorac Dis. 2014;6(10):E242-5.

XXI. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW. Primary pulmonary lymphoma. Ann Thorac Surg. 2005;80(4):1248-53.

XXII. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85(4):1075-82.

XXIII. Yoon RG, Kim MY, Song JW, Chae EJ, Choi CM, Jang S. Primary endobronchial marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: CT findings in 7 patients. Korean J Radiol. 2013;14(2):366-74.